Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
NCT05514132Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ceralasertib in solid tumor (advanced stage), sponsored by AstraZeneca. Primary endpoints: Dose-Limiting Toxicity and Adverse Events. Started Sep 2022; status: active, not recruiting.
02
Drugs
ceralasertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05514132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514132.